01
Generative design
Diffusion-model architecture generates 10,000 candidate molecules from a single target binding profile.
HELIX ⏤ bio
Request demo → NASDAQ: HLIX · Series C closed
Drug discovery,
at the speed of code.
The first AI-native lab platform. Design molecules, simulate pharmacokinetics, and ship to wet-lab validation — all from one workspace, in days, not years.
2,400+
candidate molecules / day
$1.4B
in pre-clinical savings
94.2%
simulation correlation
— THE PLATFORM
One stack. From design to dose.
02
In-silico screening
Quantum-mechanical force-field simulation ranks by affinity, ADMET, and synthesisability — in minutes.
03
Wet-lab handoff
Direct integration with Strateos, Emerald Cloud Lab, and on-prem robotic synthesis. Order from the IDE.
04
Clinical readiness
IND-package generation, regulatory writing, and audit-ready experiment trails baked in.
— PIPELINE · Q4 2026
Eleven assets, three IND filings.
Asset
Indication
Phase
Status
HLX-301
Triple-neg breast cancer
Pre-clinical
▲ ON TRACK
HLX-407
Pancreatic adenocarcinoma
IND-enabling
▲ ON TRACK
HLX-512
Glioblastoma multiforme
Discovery
▲ AHEAD
HLX-618
NASH · F3 fibrosis
Lead opt.
▲ ON TRACK
HLX-724
Alzheimer's (Aβ-protein)
Discovery
▲ ON TRACK
Set a date.
See the platform.
Demos are run by our co-founders — not by sales. 45 minutes. Bring your hardest target.
Request a demo →